Pretreatment patient characteristics
| Variable . | All patients (n = 25) . | Treatment-naïve patients (n = 11) . | R/R disease (n = 14) . |
|---|---|---|---|
| Median age, y (range) | 63 (42-88) | 63 (49-88) | 65 (47-83) |
| Sex | |||
| Male | 15 (60) | 5 (45) | 10 (71) |
| Female | 10 (40) | 6 (55) | 4 (29) |
| Race | |||
| White | 22 (88) | 8 (73) | 14 (100) |
| Asian/Pacific islander | 2 (8) | 2 (18) | 0 |
| Black | 1 (4) | 1 (9) | 0 |
| Ethnicity | |||
| Non-Hispanic | 22 (88) | 9 (82) | 13 (93) |
| Hispanic | 3 (12) | 2 (18) | 1 (7) |
| ECOG performance score | |||
| 0 | |||
| 1 | |||
| 2 | |||
| PTCL subtype | |||
| Angioimmunoblastic T-cell lymphoma | 14 (56) | 5 (45) | 9 (65) |
| Peripheral T-cell lymphoma-NOS | 4 (16) | 2 (18) | 2 (14) |
| Peripheral T-cell lymphoma-TFH | 3 (12) | 3 (27) | |
| Anaplastic large cell lymphoma | 1 (4) | 1 (7) | |
| Adult T-cell leukemia/lymphoma | 1 (4) | 1 (9) | |
| Enteropathy-associated T-cell lymphoma | 1 (4) | 1 (7) | |
| Extranodal NK/T-cell lymphoma | 1 (4) | 1 (7) | |
| Stage at study entry | |||
| I-II | 3 (12) | ||
| III-IV | 22 (88) | ||
| Median No. of previous therapies (range) | 2 (1-6) | ||
| Previous chemotherapy regimens | |||
| Anthracycline-based* | 11 (78) | ||
| HDAC inhibitor monotherapy | 5 (36) | ||
| Platinum-based† | 4 (29) | ||
| Pralatrexate monotherapy | 1 (7) | ||
| Brentuximab vedotin-based‡ | 1 (7) | ||
| Other therapy/experimental drug | 6 (43) | ||
| ASCT | 4 (29) | ||
| Radiotherapy | 1 (7) |
| Variable . | All patients (n = 25) . | Treatment-naïve patients (n = 11) . | R/R disease (n = 14) . |
|---|---|---|---|
| Median age, y (range) | 63 (42-88) | 63 (49-88) | 65 (47-83) |
| Sex | |||
| Male | 15 (60) | 5 (45) | 10 (71) |
| Female | 10 (40) | 6 (55) | 4 (29) |
| Race | |||
| White | 22 (88) | 8 (73) | 14 (100) |
| Asian/Pacific islander | 2 (8) | 2 (18) | 0 |
| Black | 1 (4) | 1 (9) | 0 |
| Ethnicity | |||
| Non-Hispanic | 22 (88) | 9 (82) | 13 (93) |
| Hispanic | 3 (12) | 2 (18) | 1 (7) |
| ECOG performance score | |||
| 0 | |||
| 1 | |||
| 2 | |||
| PTCL subtype | |||
| Angioimmunoblastic T-cell lymphoma | 14 (56) | 5 (45) | 9 (65) |
| Peripheral T-cell lymphoma-NOS | 4 (16) | 2 (18) | 2 (14) |
| Peripheral T-cell lymphoma-TFH | 3 (12) | 3 (27) | |
| Anaplastic large cell lymphoma | 1 (4) | 1 (7) | |
| Adult T-cell leukemia/lymphoma | 1 (4) | 1 (9) | |
| Enteropathy-associated T-cell lymphoma | 1 (4) | 1 (7) | |
| Extranodal NK/T-cell lymphoma | 1 (4) | 1 (7) | |
| Stage at study entry | |||
| I-II | 3 (12) | ||
| III-IV | 22 (88) | ||
| Median No. of previous therapies (range) | 2 (1-6) | ||
| Previous chemotherapy regimens | |||
| Anthracycline-based* | 11 (78) | ||
| HDAC inhibitor monotherapy | 5 (36) | ||
| Platinum-based† | 4 (29) | ||
| Pralatrexate monotherapy | 1 (7) | ||
| Brentuximab vedotin-based‡ | 1 (7) | ||
| Other therapy/experimental drug | 6 (43) | ||
| ASCT | 4 (29) | ||
| Radiotherapy | 1 (7) |
Data are no. (%) unless otherwise specified.
ECOG, Eastern Cooperative Oncology Group; NK, natural killer; NOS, not otherwise specified.
Regimens include CHO(E)P, cyclophosphamide, doxorubicin, vincristine, etoposide, prednisone; EPOCH, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin.
Regiments include ICE (ifosfamide, carboplatin, etoposide); GemOx (rituximab, gemcitabine, oxaliplatin).
Regimens include bendamustine, rituximab, and vorinostat; ALRN-6924; tipifarnib; p-GemOx (peg-asparaginase, gemcitabine, oxaliplatin); bortezomib and valagancyclovir; SMILE (dexamethasone, methotrexate, ifosfamide, L-asparaginase, etoposide); BAC (bendamustine and cytarabine).